Positron emission tomography and recovery following revascularization (PARR-1): The importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function

Journal of the American College of Cardiology

Volumn 40, Issue 10, 2002, Pages 1735-1743

  Beanlands, Rob S B ^a   Ruddy, Terrence D ^a   DeKemp, Robert A ^a   Iwanochko, Robert M ^b   Coates, Geoffrey ^c   Freeman, Michael ^b   Nahmias, Claude ^c   Hendry, Paul ^a   Burns, Robert J ^b   Lamy, Andre ^d   Mickleborough, Lynda ^b   Kostuk, William ^e   Fallen, Ernest ^d   Nichol, Graham ^f  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c HAMILTON HEALTH SCIENCES   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e LONDON HEALTH SCIENCES CENTRE   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGE; AGED; ARTICLE; CELL VIABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART DISEASE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OPERATION DURATION; OUTCOMES RESEARCH; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; SCAR FORMATION; SCINTIANGIOGRAPHY; SCORING SYSTEM;

AGED; CANADA; CICATRIX; COHORT STUDIES; CORONARY ARTERIOSCLEROSIS; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL REVASCULARIZATION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIONUCLIDE ANGIOGRAPHY; RADIOPHARMACEUTICALS; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; STATISTICS; STROKE VOLUME; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 0037145936     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02489-0     Document Type: Article

References (61)

1. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the cooperative North Scandinavian enalapril survival study. N Engl J Med 1987;316:1429-35.
2. Di Carli MF, Davidson M, Little R, et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol 1994;73:527-33.
3. Alderman EL, Fisher LD, Litwin P, et al. Results of coronary artery surgery in patients with poor left ventricular function (CASS). Circulation 1983;68:785-95.
4. Maddahi J, Schelbert H, Brunken R, Di Carli M. Role of thallium-201 and PET imaging in evaluation of myocardial viability and management of patients with coronary artery disease and left ventricular dysfunction. J Nucl Med 1994;35:707-15.
5. Eitzman D, Al-Aouar Z, Kanter HL, et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol 1992;20:559-65.
6. Beanlands RS, Hendry P, Masters R, deKemp RA, Woodend K, Ruddy TD. Delay in revascularization is associated with increased mortality rate in patients with severe LV dysfunction and viable myocardium on fluorine-18-fluorodeoxyglucose positron emission tomography imaging. Circulation 1998;98 Suppl II:51-6.
7. Lee KS, Marwick TH, Cook SA, et al. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction: Relative efficacy of medical therapy and revascularization. Circulation 1995;90:2687-94.
8. Sawada S, Muzik O, Allman K, et al. Positron emission tomography detects evidence of viability in rest technetium-99m sestamibi defects. J Am Coll Cardiol 1994;23:92-8.
9. Bax JJ, Cornel JH, Visser FC, et al. Prediction of recovery of regional ventricular dysfunction following revascularization: Comparison of F-18 fluorodeoxyglucose SPECT, thallium-201 stress-reinjection SPECT and dobutamine echocardiography. J Am Coll Cardiol 1996;28:558-64.
10. Di Carli M. Predicting improved function after myocardial revascularization. Curr Opin Cardiol 1998;13:415-24.
11. Pagano D, Bonser RS, Townend J, Ordoubadi F, Lorenzoni R, Camici P. Predictive value of dobutamine echocardiography and positron emission tomography in identifying hibernating myocardium in patients with postischaemic heart failure. Heart 1998;79:281-8.
12. Tamaki N, Kawamoto M, Takahashi N, et al. Prognostic value of an increase in fluorine-18 deoxyglucose uptake in patients with myocardial infarction: Comparison with stress thallium imaging. J Am Coll Cardiol 1993;22:1621-7.
13. Tamaki N, Yonekura Y, Yamashita K, et al. Positron emission tomography using fluorine-18-deoxyglucose in evaluation of coronary artery bypass grafting. Am J Cardiol 1989;64:860-5.
14. Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986;314:884-8.
15. vom Dahl J, Eitzman DT, Al-Aouar ZR, et al. Relation of regional function, perfusion, and metabolism in patients with advanced coronary artery disease undergoing surgical revascularization. Circulation 1994;90:2356-65.
16. Carrel T, Jenni R, Haubold-Reuter S, von Schulthess G, Pasic M, Turina M. Improvement of severely reduced left ventricular function after surgical revascularization in patients with preoperative myocardial infarction. Eur J Nucl Med 1992;6:479-84.
17. Lucignani G, Paolini G, Landoni C, et al. Presurgical identification of hibernating myocardium by combined use of technetium-99m hexakis 2-methoxyisobutylisonitrile single photon emission tomography and fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography in patients with coronary artery disease. Eur J Nucl Med 1992;19:874-81.
18. Bax JJ, Poldermans D, Elhendy A, Boersma E, Rahimtoola SH. Sensitivity, specificity, and predictive accuracies of various noninvasive techniques for detecting hibernating myocardium. Curr Probl Cardiol 2001;26:141-86.
19. Pagano D, Townend J, Littler W, Horton R, Camici P, Bonser R. Coronary artery bypass surgery as treatment for ischemic heart failure: The predictive value of viability assessment with quantitative positron emission tomography for symptomatic and functional outcome. J Thorac Cardiovasc Surg 1998;115:791-9.
20. Haas F, Haehnel C, Picker W, et al. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol 1997;30:1693-700.
21. Calhoun WB, Mills RM, Drane WE. Clinical importance of viability assessment in chronic ischemic heart failure. Clin Cardiol 1996;19:367-9.
22. Beanlands RSB, deKemp RA, Smith S, Johansen H, Ruddy TD. F-18-fluorodeoxyglucose PET imaging alters clinical decision making in patients with impaired ventricular function. Am J Cardiol 1997;79:1092-5.
23. Auerbach M, Schoder H, Hob CK, et al. Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy. Circulation 1999;99:2921-6.
24. Akinboboye OO, Idris O, Cannon P, Bergmann S. Usefulness of positron emission tomography in defining myocardial viability in patients referred for cardiac transplantation. Am J Cardiol 1999;83:1271-4.
25. Calhoun WB, Mills RM, Drane WE. Clinical importance of viability assessment in chronic ischemic heart failure. Clin Cardiol 1996;19:367-9.
26. Bristow MR, O'Connell JB, Gilbert EM, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idioparhic dilated or ischemic cardiomyopathy. Circulation 1994;89:1632-42.
27. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: Reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Am Heart J 1992;124:1017-25.
28. Gilbert EM, Yanowitz FG, Anderson JL, O'Connell JB, Bristow MR. Effect of long term beta-blockade with metoprolol on exercise tolerance in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1993;21:115A.
29. Guyatt GH, Nogradi S, Singer J, Sullivan MJJ, Fallen EL. Development and testing of a new measure of health status for clinical trials in heart failure. J Gen Intern Med 1989;4:101-7.
30. Yu EHC, Sloggett CE, Iwanochko RM, Rakowski H, Siu SC. Feasibility and accuracy of left ventricular volumes and ejection fraction determination by fundamental tissue harmonic and intravenous contrast imaging in difficult-to-image patients. J Am Soc Echocardiogr 2000;13:216-24.
31. Burns RJ, Nitkin RS, Weisel RD, et al. Optimized count-based scintigraphic left ventricular volume measurement. Can J Cardiol 1985;1:42-6.
32. Fallen EL, Nahmias C, Scheffel A, Coates G, Beanlands RSB, Garnet ES. Redistribution of myocardial blood flow with topical nitroglycerin in patients with coronary artery disease. A PET study. Circulation 1995;91:1381-8.
33. Rothley J, Weeden ARJ. Clinical PET protocols. In: Schwaiger M, editor. Cardiac Positron Emission Tomography. Kluwer Academic Publishers, 1996:357.
34. Tamaki N, Ohtani H, Yamashita K, et al. Metabolic activity in the areas of new fill-in after thallium-201 reinjection: Comparison with positron emission tomography using fiuorine-018-deoxyglucose. J Nucl Med 1991;32:673-8.
35. Yoshida K, Gould KL. Quantitative relation of myocardial infarct size and myocardial viability by positron emission tomography to left ventricular ejection fraction and 3-year mortality with and without revascularization. J Am Coll Cardiol 1993;22:984-97.
36. Beanlands RSB, Muzik O, Melon P, et al. Noninvasive quantification of regional myocardial flow reserve in stenosed and angiographically normal vessels of patients with coronary atherosclerosis. J Am Coll Cardiol 1995;26:1465-75.
37. Beanlands R, Muzik O, Hutchins G, Schwaiger M. Noninvasive quantification of myocardial perfusion using positron emission tomography. Coron Artery Dis 1992;3:281-90.
38. Beanlands RSB, deKemp R, Scheffel A, et al. Can nitrogen-13 ammonia kinetic modeling define myocardial viability, independent of fluorine-18 fluorodeoxyglucose? J Am Coll Cardiol 1997;29:537-43.
39. Beauchesne LM, Ruddy TD, deKemp RA, et al. Reproducibility of myocardial perfusion measurements with PET rubidium-82 imaging. Circulation 1998;98:1222.
40. Scott NS, LeMay M, deKemp R, et al. Evaluation of myocardial perfusion using rubidium-82 positron emission tomography after myocardial infarction in patients receiving primary stent implantation or thrombolyic therapy. Am J Cardiol 2001;88:886-9.
41. deKemp R, Ruddy TD, Hewitt T, Dalipaj M, Beanlands R. Detection of serial changes in absolute myocardial perfusion with 82-Rb PET. J Nud Med 2000;41:1426-35.
42. vom Dahl J, Altehoefer C, Sheehan FH, Buechin P, et al. Effect of myocardial viability assessed by technetium-99m-sestamibi SPECT and fluorine-18-FDG PET on clinical outcome in coronary artery disease. J Nud Med 1997;38:742-8.
43. deKemp RA, Nahmias C. Automated determination of the left ventricular long axis in cardiac positron emission. Physiol Meas 1996;17:95-108.
44. Concato J, Feinstein AR. Monte Carlo methods in clinical research: Applications in multivariable analysis. J Invest Med 1997;45:394-400.
45. Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. Ann Intern Med 1993;118:201-10.
46. Harrell FE, Jr. General aspects of fitting regression models. In: Regression Modeling Strategies with Applications to Linear Models, Logistic Regression and Survival Analysis. New York, NY: Springer, 2001.
47. Soufer R, Dey H, Ng C-K, Zaret B. Comparison of sestamibi single-photon emission computed tomography with positron emission tomography for estimating left ventricular myocardial viability. Am J Cardiol 1995;75:1214-9.
48. Dilsizian V, Arrighi JA, Diodati JG, et al. Myocardial viability in patients with chronic coronary artery disease. Comparison of 99mTc-sestamibi with thallium reinjection and [18F]fluorodeoxyglucose. Circulation 1994;89:578-87.
49. Bax JJ, Visser FC, Cornel JH, et al. Prediction of improvement of left ventricular function and heart failure symptoms by FDG SPECT (abstr). J Am Coll Cardiol 1998;31:1129-43.
50. Bax JJ, Cornel JH, Visser FC, Fioretti PM, Van Lingen A, Visser CA. Differentiating viability criteria on F18-fluorodeoxyglucose imaging for the optimal prediction of functional recovery after revascularization (abstr). J Am Coll Cardiol 1998;31:1129-44.
51. Haas F, Augustin N, Holper K, et al. Time course and extent of improvement of dysfunctioning myocardium in patients with coronary, artery disease and severely depressed left ventricular function after revascularization: Correlation with positron emission tomography. J Am Coll Cardiol 2000;36:1927-34.
52. Haas F, Jennen L, Heinzmann U, et al. Ischemicaily compromised myocardium displays different time-courses of functional recovery: Correlation with morphological alterations? Eur J Cardiothorac Surg 2001;20:290-8.
53. Siebelink H-MJ, Blanksma PK, Crijns HJGM, et al. No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided management. J Am Coll Cardiol 2001;37:81-8.
54. Beanlands RS, Ruddy TD, Freeman MR, Nichol G. Patient management guided by viability imaging. J Am Coll Cardiol 2001;38:1271-2.
55. GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-22.
56. vom Dahl J, Herman WH, Hicks RJ, et al. Myocardial glucose uptake in patients with insulin-dependent diabetes mellitus assessed quantitatively by dynamic positron emission tomography. Circulation 1993;88:395--404.
57. Ohtake T, Yokoyama I, Watanabe T, et al. Myocardial glucose metabolism in non-insulin dependent diabetes mellitus patients evaluated by FDG-PET. J Nucl Med 1995;36:456-63.
58. Marinho NVS, Keogh BE, Costa DC, Lannerstma AA, Ell PJ, Camici PG. Pathophysiology of chronic left ventricular dysfunction: New insights from the measurement of absolute myocardial blood flow and glucose utilization. Circulation 1996;93:737-44.
59. Maki M, Luotolahti M, Nuutila P, et al. Glucose uptake in the chronically dysfunctional but viable myocardium. Circulation 1996;93:1658-66.
60. Vitale G, deKemp R, Ruddy TD, Williams K, Beanlands RSB. Myocardial glucose utilization and the optimization of F-18 FDG PET imaging in patients with non-insulin dependent diabetes mellitus, coronary artery disease and left ventricular dysfunction. J Nucl Med 2001;42:1730-6.
61. Bax JJ, Visser FC, Poldermans D, et al. Time course of functional recovery of stunned and hibernating segments after surgical revascularlzation. Circulation 2001;104 Suppl I:1314-8.